About Sol-Gel Technologies
Sol-Gel Technologies is a publicly listed company based in United States founded in 1998 by Alon Seri-Levy and David Avnir. Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. Sol-Gel Technologies has raised $9 million across 8 funding rounds from investors including National Science Foundation. The company has 34 employees. Sol-Gel Technologies has completed 1 acquisition, including Patidegib. Its chief executive, as recorded, is Alon Seri-Levy. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its competitors include Revance Therapeutics, Dermavant and SkinMedica; 3 of its 3 listed competitors have raised funding.
Company details
Sol-Gel is a clinical-stage specialty pharma focused on developing topical dermatological drug products. Its drug pipeline includes VERED (Phase 2), a topical encapsulated benzoyl peroxide cream for the treatment of papulopustular rosacea; TWIN (Phase 2), a non-antibiotic topical cream and SIRS-T (PreclinicalPhase 1), a topical encapsulated tretinoin cream for the treatment of acne vulgaris E-06 (preclinicalphase 1), a cream formulation of a new fixed-dose combination, containing an antifungal agent and a mid-potency steroid for the treatment of symptomatic c(athletes foot). All its products are based on its proprietary microencapsulation delivery system.
- Headquarters United States
- Employees 34
- Founders Alon Seri-Levy, David Avnir
- Stage Public
- SectorsHealthcare
- Website sol-gel.com
- Social LinkedIn
- Legal Name Sol-Gel Technologies Ltd.
- Annual Revenue$19.39 M (USD)68.04as on Dec 31, 2025
- Net Profit-$6.13 M (USD)42.09as on Dec 31, 2025
- EBITDA-$7.48 M (USD)36.48as on Dec 31, 2025
- Total Equity Funding$9M (USD)
in 8 rounds
- Latest Funding Round$5M (USD), Post-IPO
Apr 2020
- Investors
- Employee Count34
- Investments & Acquisitions
Funding Insights of Sol-Gel Technologies
Sol-Gel Technologies has successfully raised a total of $9M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9M
- Total Rounds 8
- Last Round Post-IPO — $5M
- First Round $149,752
(Oct 2007)
- Investors Count 1
All 8 funding rounds of Sol-Gel Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $5M | Post-IPO | – | – | – |
| May 2009 | $524,423 | Grant | – | – | |
| Jan 2009 | $99,103 | Grant | – | – | |
| Nov 2008 | $9M | Series A | – | – | – |
| Nov 2008 | $99,103 | Grant | – | – | |
| Jan 2008 | $674,175 | Grant | – | – | |
| Dec 2007 | $524,423 | Grant | – | – | |
| Oct 2007 | $149,752 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Sol-Gel Technologies
Sol-Gel Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Sol-Gel Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sol-Gel Technologies
17 people are tracked at Sol-Gel Technologies (6 in leadership, 11 in team); the tracked headcount is 34.
| Name | Role | Group |
|---|---|---|
Alon Seri-Levy | Co-Founder & CEO | Leadership |
David Avnir | Co-Founder | Leadership |
John Vieira | U.S. Head of Commercialization | Leadership |
Itzik Yosef | Chief Operating Officer | Leadership |
Ofra Levy-Hacham | VP Clinical and Regulatory Affairs | Leadership |
Orit Zur | Head Of HR | Leadership |
Hila Hakak | Alliance Manager | Team |
Evgenia Marchenko | RA Manager | Team |
Debbie Weiss | Documentation Center Administrator | Team |
Bsc Dana Green | Operations Manager | Team |
Ina Tulchinsky Mazor | Clinical Research Associate | Team |
Orit Asseraf | Supply Chain Manager | Team |
Gaby Peleg | Administration Manager | Team |
Luba Katz | Clinical Research Associate | Team |
Gadi Kornfeld | R D | Team |
Shevik Packman | Administrative Manager | Team |
Ronit Yafeh | RA Special Project Manager | Team |
Complete people profiles for Sol-Gel Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sol-Gel Technologies
Sol-Gel Technologies is a publicly listed company on the NASDAQ with ticker symbol SLGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Jan 2018
- Listed onNASDAQ: SLGL
- Listed entitySol-Gel Technologies Ltd.
- Exchange sectorHealth technology
- ISINIL0011417206
- Share price$68.30 (-5.66% on the day) · 2026-10-13
- Market capitalisation$223.6M
- EPS (diluted, trailing year)$-5.64
- Volume (last session)33,736
Financials of Sol-Gel Technologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $19.4M | -$6.1M | -$7.5M |
| 2024 | $11.5M | -$10.6M | -$11.8M |
| 2023 | $1.6M | -$27.2M | -$29.0M |
| 2022 | $3.9M | -$14.9M | -$15.7M |
| 2021 | $31.3M | $3.2M | $3.3M |
Detailed financial statements for Sol-Gel Technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sol-Gel Technologies
Sol-Gel Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Patidegib.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cancer therapy drug development services are provided by Patidegib. | 0 | Jan 2023 | •••• |
Complete acquisition details for Sol-Gel Technologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sol-Gel Technologies
5 dated milestones of Sol-Gel Technologies across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Sol-Gel Technologies is founded.
- Funding First funding round of $150K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $5.0M.
- Acquisition Acquires Patidegib.
Competitors of Sol-Gel Technologies
Sol-Gel Technologies has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Dermavant and SkinMedica.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. | ||
| skinmedica.com | 1999 | Carlsbad, United States | $94.24M | Skin care products are developed and manufactured by SkinMedica. |
Detailed competitors of Sol-Gel Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sol-Gel Technologies
The website of Sol-Gel Technologies (sol-gel.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▼ 4.8% vs previous month
Websites whose visitors overlap most with Sol-Gel Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
capsulution.com | capsulution.com | 100% | #3,311,802 | – | |
| hybridplastics.com | 100% | 1.8K | #6,871,765 | View details | |
| flamel.com | 100% | View details | |||
| atdbio.com | 100% | 29.3K | #886,988 | View details | |
| firstnano.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Sol-Gel Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Sol-Gel Technologies (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sol-Gel Technologies
Complete news archive for Sol-Gel Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sol-Gel Technologies
Sol-Gel Technologies was founded in 1998 and raised its 1st funding round 9 years after it was founded.
Sol-Gel Technologies is headquartered in United States.
Alon Seri-Levy is the CEO of Sol-Gel Technologies, as recorded in our data. They have also founded this company.
Sol-Gel Technologies is a funded company, having raised a total of $9M across 8 funding rounds to date. The company's 1st funding round was a Grant of $149.75K, raised on Oct 2007.
Sol-Gel Technologies has 34 employees.
Annual revenue of Sol-Gel Technologies is $19.39M as on Dec 31, 2025.
Sol-Gel is a clinical-stage specialty pharma focused on developing topical dermatological drug products. Its drug pipeline includes VERED (Phase 2), a topical encapsulated benzoyl peroxide cream for the treatment of papulopustular rosacea; TWIN (Phase 2), a non-antibiotic topical cream and SIRS-T (PreclinicalPhase 1), a topical encapsulated tretinoin cream for the treatment of acne vulgaris E-06 (preclinicalphase 1), a cream formulation of a new fixed-dose combination, containing an antifungal agent and a mid-potency steroid for the treatment of symptomatic c(athletes foot). All its products are based on its proprietary microencapsulation delivery system.
Sol-Gel Technologies's top competitors include Revance Therapeutics, Dermavant and SkinMedica.
Yes, Sol-Gel Technologies is publicly traded on NASDAQ under the ticker symbol SLGL.
Sol-Gel Technologies has made 1 acquisition, including Patidegib.
Sol-Gel Technologies has 1 investor. Key investors include National Science Foundation.